Top 10 Strategies to Change the Course of T1D
Tailored Learning for Primary Care and Specialty Teams
The multidisciplinary team in diagnosing and treatment of patients with diabetes and comorbidities: a scoping review.
Andersen JD, Jensen MH, Vestergaard P, Jensen V, Hejlesen O, Hangaard S. J Multimorb Comorb. 2023;13:26335565231165966.
The role of the diabetes care and education specialist in screening and monitoring for type 1 diabetes.
Association of Diabetes Care & Education Specialists. Sci Diabetes Self Manag Care. 2025;51(3):345-351.
C-peptide levels in subjects followed longitudinally before and after type 1 diabetes diagnosis in TrialNet.
Bogun MM, Bundy BN, Goland RS, Greenbaum CJ. Diabetes Care. 2020;43(8):1836-1842.
Type 1 diabetes presenting in adults: trends, diagnostic challenges and unique features.
Evans-Molina C, Oram RA. Diabetes Obes Metab. 2025;27(suppl 6):57-68.
Type 1 diabetes screening and diagnosis.
Gomez P, Sanchez J. Endocrinol Metab Clin North Am. 2024;53(1):17-26.
A key to T1D prevention: screening and monitoring relatives as part of clinical care.
Greenbaum CJ. Diabetes. 2021;70(5):1029-1037.
Early detection of β-cell decline using home dried blood spot C-peptide levels in new-onset type 1 diabetes.
Hendriks AEJ, Marcovecchio ML, Evans ML, et al. Diabetes Care. 2025;48(9):1484-1492.
An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes.
Herold KC, Bundy BN, Long SA, et al. N Engl J Med. 2019;381(7):603-613.
Recommendations for screening and monitoring the stages of type 1 diabetes in the immune therapy era.
Moore DJ, Leibel NI, Polonsky W, Rodriguez H. Int J Gen Med. 2024;17:3003-3014.
Teplizumab and β-cell function in newly diagnosed type 1 diabetes.
Ramos EL, Dayan CM, Chatenoud L, et al. N Engl J Med. 2023;389(23):2151-2161.
Screening for type 1 diabetes in the general population: a status report and perspective.
Sims EK, Besser REJ, Dayan C, et al. Diabetes. 2022;71(4):610-623.
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
Sims EK, Bundy BN, Stier K, et al. Sci Transl Med. 2021;13(583):eabc8980.
Genetic risk and transition through preclinical stages of type 1 diabetes.
Steck AK, Parikh HM, Triolo TM, et al. J Clin Endocrinol Metab. 2025. [Epub ahead of print]
CLINICAL PRACTICE GUIDELINES
Standards of Care in Diabetes—2026.
American Diabetes Association Professional Practice Committee. Diabetes Care. 2026;49(suppl 1).
ISPAD Clinical Practice Consensus Guidelines 2024: screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes.
Haller MJ, Bell KJ, Besser REJ, et al. Horm Res Paediatr. 2024;97(6):529-545.
Pediatric Endocrine Society statement on considerations for use of teplizumab (Tzield™) in clinical practice.
Mehta S, Ryabets-Lienhard A, Patel N, et al. Horm Res Paediatr. 2025;98(5):597-608.
Consensus guidance for monitoring individuals with islet autoantibody–positive pre-stage 3 type 1 diabetes.
Phillip M, Achenbach P, Addala A, et al. Diabetes Care. 2024;47(8):1276-1298.
CLINICIAN AND PATIENT RESOURCES
ASK.
Barbara Davis Center for Diabetes.
Type 1 diabetes TrialNet.
TrialNet.
We are Breakthrough T1D.
Breakthrough T1D.
Spot T1D Early, Act Sooner
Answers to Top 10 Questions About Recognizing and Responding to Early T1D
| Faculty: | Bithika M. Thompson, MD |
| Release: | 01/30/2026 |
| Expiration: | 01/30/2027 |
Delivering Disease-Modifying Therapy in T1D
10 Tips for Endocrinology and Infusion Teams
| Faculty: | Emily K. Sims, MD, MS |
| Release: | 01/30/2026 |
| Expiration: | 01/30/2027 |
